Publikationen in Zusammenarbeit mit Forschern von Fundación Jiménez Díaz (64)

2014

  1. Impact of isolated hepatitis C virus (HCV) core-specific antibody detection and viral RNA amplification among HCV-seronegative dialysis patients at risk for infection

    Journal of Clinical Microbiology, Vol. 52, Núm. 8, pp. 3053-3056

2004

  1. Virus-Specific Effector CD4+ T-Cell Responses in Hemodialysis Patients with Hepatitis C Virus Infection

    Journal of Medical Virology, Vol. 72, Núm. 1, pp. 66-74

2003

  1. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease

    Archives of Neurology, Vol. 60, Núm. 9, pp. 1218-1222

  2. Niveles de proteína tau y β-amiloide en la demencia con cuerpos de Lewy en comparación con la enfermedad de Alzheimer

    Mapfre Medicina, Vol. 14, Núm. 2, pp. 118-124

2002

  1. Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates

    Parkinsonism and Related Disorders, Vol. 8, Núm. 5, pp. 311-323

  2. Features of the CD4+ t-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels

    Journal of Hepatology, Vol. 36, Núm. 3, pp. 408-416

  3. Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation

    Journal of Alzheimer's Disease, Vol. 4, Núm. 5, pp. 399-404

  4. Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein

    Movement Disorders, Vol. 17, Núm. 6, pp. 1374-1380

2001

  1. Expression of factor VII in the liver of patients with liver disease: Correlations with the disease severity and impairment in the hemostasis

    Blood Coagulation and Fibrinolysis, Vol. 12, Núm. 3, pp. 193-199

2000

  1. Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: Evaluation of the bleeding risk

    Blood Coagulation and Fibrinolysis

  2. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients

    Hepatology, Vol. 31, Núm. 2, pp. 502-506

  3. Randoimized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C

    Cytokine, Vol. 12, Núm. 2, pp. 165-170

  4. Role of haemodialysis and hepatitis C virus infection in spontaneous and induced cytokine production of patients with chronic renal disease

    Cytokine, Vol. 12, Núm. 8, pp. 1248-1252

1999

  1. Cinetica del interferon α-2a en pacientes en hemodialisis

    Nefrologia, Vol. 19, Núm. 3, pp. 268-270

  2. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus

    Journal of Infectious Diseases, Vol. 180, Núm. 2, pp. 262-267

  3. Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells

    Cytokine, Vol. 11, Núm. 4, pp. 267-273

  4. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a

    Hepatology, Vol. 30, Núm. 1, pp. 277-282

1998

  1. Effects of the ribavirin-interferon α combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients

    Cytokine, Vol. 10, Núm. 8, pp. 635-644

  2. Induction of interleukin-12 production in chronic hepatitis C virus infection correlate with the hepatocellular damage

    Journal of Infectious Diseases, Vol. 178, Núm. 1, pp. 247-251

1997

  1. Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection.

    Journal of viral hepatitis, Vol. 4 Suppl 2, pp. 83-86